AFFINIVAX

GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines... GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

Also known as: Affinivax, Inc., GSK

Registration numbers: 3888792 (W), FN 115955y (W)

VAT numbers: ATU 14215008

Primary location: Brentford United Kingdom